Intercept Pharmaceut (ICPT) 169.72 $ICPT BioMarin (BMRN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intercept Pharmaceut (ICPT) 169.72 $ICPT

BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:04AM CDT
BioMarin (BMRN), which is scheduled to report second-quarter 2016 results on Aug 4, had delivered a positive earnings surprise of 58.82% last quarter.
BMRN: 100.25 (+0.83), CNAT: 2.29 (+0.03), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)

Zoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:01AM CDT
Zoetis (ZTS), which is set to report second-quarter 2016 results on Aug 3, had delivered a positive earnings surprise of 17.07% last quarter.
ZTS: 50.40 (-0.07), ABT: 45.29 (+0.54), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)

Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 2:51PM CDT
Pfizer (PFE), which is set to report second-quarter 2016 results on Aug 2, had delivered a positive earnings surprise of 21.82% last quarter. Will it beat estimates again?
BMRN: 100.25 (+0.83), PFE: 37.31 (+0.42), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)

Intercept to Report Second Quarter 2016 Financial Results on August 4 and Present at Upcoming Conference
GlobeNewswire - Thu Jul 28, 6:06AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its second quarter 2016 financial results prior to the NASDAQ market open on Thursday, August 4, 2016. Intercept management will conduct a conference call and audio webcast on Thursday, August 4, 2016 at 8:30 a.m. Eastern Time to discuss these results.
ICPT: 169.72 (-3.31)

AbbVie (ABBV) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 9:11AM CDT
Will Imbruvica and Humira help AbbVie (ABBV) deliver a positive earnings surprise in Q2?
JNJ: 125.40 (+0.17), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), BMY: 76.19 (+1.38)

Merck (MRK) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 6:24AM CDT
Merck (MRK) had posted a positive earnings surprise in Q1. Will the stock deliver a positive surprise again this quarter?
BMRN: 100.25 (+0.83), MRK: 58.66 (unch), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13)

Vertex (VRTX) to Report Q2 Earnings: Is a Surprise in Store?
Arpita Dutt - Zacks Investment Research - Mon Jul 25, 6:54AM CDT
Will Orkambi and Kalydeco help Vertex (VRTX) surpass expectations in Q2?
VRTX: 98.20 (+1.20), BMRN: 100.25 (+0.83), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13)

Amgen (AMGN) May Beat Q2 Earnings: Will the Stock Gain?
Arpita Dutt - Zacks Investment Research - Mon Jul 25, 6:36AM CDT
Our proven model shows that Amgen (AMGN) is likely to beat earnings because it has the right combination of two key ingredients.
BMRN: 100.25 (+0.83), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13), FMS: 45.65 (unch)

Intercept Pharmaceuticals Announces Closing of Public Offering of Convertible Senior Notes and Exercise in Full of Option to Purchase Additional Notes
GlobeNewswire - Wed Jul 06, 4:05PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today the closing of its previously announced underwritten public offering of $460 million aggregate principal amount of 3.25% convertible senior notes due 2023 (the notes), including the full exercise by the underwriters of an option to purchase an additional $60 million in aggregate principal amount of notes to cover over-allotments. As a result, Intercept anticipates that the aggregate net proceeds, after deducting the underwriting discount and estimated offering expenses payable by Intercept, will be approximately $447.7 million.
ICPT: 169.72 (-3.31)

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of Intercept Pharmaceuticals, Inc. Securities Litigation
PR Newswire - Mon Jun 20, 10:30AM CDT
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Intercept Pharmaceuticals, Inc. Securities Litigation:
ICPT: 169.72 (-3.31)

Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer
GlobeNewswire - Thu Jun 09, 4:35PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the appointment of Sandip Kapadia as Chief Financial Officer. Mr. Kapadia will succeed Barbara Duncan effective July 1, who has served as CFO for Intercept since 2009. Ms. Duncan and Mr. Kapadia will work closely through a transition period to support a seamless change in leadership.
ICPT: 169.72 (-3.31)

The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 301.83 (+11.90), SRPT: 25.91 (+0.63), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), IONS: 38.01 (+8.82)

Intercept to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 3:05PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences:
ICPT: 169.72 (-3.31)

Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), SRPT: 25.91 (+0.63), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), IONS: 38.01 (+8.82)

Intercept's (ICPT) Liver Dug Ocaliva Approved by the FDA
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:46AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA has granted accelerated approval to Ocaliva (obeticholic acid), in combination with ursodeoxycholic (UDCA).
ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), ICPT: 169.72 (-3.31), BMY: 76.19 (+1.38)

FDA Grants Accelerated Approval to Ocaliva(TM) (Obeticholic Acid) for the Treatment of Patients with PBC
GlobeNewswire - Fri May 27, 10:42PM CDT
First new medicine for PBC in nearly 20 years
ICPT: 169.72 (-3.31)

Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 98.20 (+1.20), HZNP: 18.89 (-0.40), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), ACOR: 25.13 (-0.15), BIOD: 0.41 (-0.03), XNPT: 7.07 (+0.05)

Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma
PR Newswire - Wed May 25, 7:10AM CDT
The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:
IMMU: 2.80 (+0.15), RARE: 63.53 (+0.25), ICPT: 169.72 (-3.31), JUNO: 30.86 (-0.07)

Adaptimmune Strengthens Board with Appointment of Barbara Duncan
GlobeNewswire - Tue May 24, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP) ("Adaptimmune" or the "Company", a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee.
MDGN: 6.03 (+0.26), ICPT: 169.72 (-3.31), ADAP: 8.35 (+0.23)

Intercept Announces Ocaliva(TM) (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
GlobeNewswire - Wed May 18, 10:00AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, announced today that five abstracts evaluating obeticholic acid (OCA) in patients with primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) will be presented at Digestive Disease Week (DDW) in San Diego, California from May 21-24, 2016. OCA is an investigational product and has not been granted marketing authorization or approval from any regulatory authority.
ICPT: 169.72 (-3.31)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 77

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 119

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 172

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 107

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
J. Harmon Tests a Smarter Cannabis Accessory Niche

Updated Category News Views 53

Aisle Space Is the Real Prize Most cannabis accessory launches arrive dressed up like a gimmick and disappear before anyone has reordered them. J. Harmon has a more sensible target: give women products that look deliberate, work in everyday routines and do not demand designer-level money. The brand is set to debut at MJBizCon 2026 in Las Vegas, with LUVBUDS handling...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 102

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Chainlink, UBS Take $2 Trillion Notes Toward Onchain

Updated Category News Views 9

Paperwork is a lousy moat when a bank can automate the mess. Chainlink and UBS are putting that proposition to work in structured notes, a market with more than $2 trillion in outstanding notional and, frankly, an awful lot of operational clutter. Their production solution uses the Chainlink Runtime Environment, or CRE, to connect UBS systems, smart contracts, market data...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 226

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 89

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Colon Cleanse Advice Deserves a Careful Read First

Updated Category News Views 23

Wellness copy can sound harmless right up until it blurs comfort guidance with health guidance. HelloNation’s feature on what to expect after a colon cleanse, drawing on Suzanne Childre of Gentle Wellness Center in Santa Monica, lays out a fairly familiar recovery script: drink water, rest, eat lightly, expect some bowel changes, and do not panic over a little fatigue....

Continue Reading

Top 5 Most Recently Viewed Articles

WM Technology Faces Class Action Lawsuit: What Investors Need to Know

Updated Category News Views 69

Understanding WM Technology's Legal Challenges WM Technology, Inc. has recently found itself at the center of a class action lawsuit, raising significant concerns among its investors. This legal action has been initiated by a prominent law firm advocating for shareholder rights, highlighting serious allegations against the company. Investors are encouraged to stay...

Continue Reading
Nimbello's SyteLine Customer Growth Signals Bright Future Ahead

Updated Category News Views 224

Nimbello's Impressive Growth in the SyteLine Market Nimbello, renowned for its innovative Accounts Payable (AP) automation solutions, has achieved a significant milestone by doubling its customer base among SyteLine users throughout the year. This exciting growth showcases Nimbello's capability and positions it as a leader within the SyteLine ecosystem. Understanding...

Continue Reading
FRE Nicotine Pouches and PBR: A Thrilling Partnership Ahead

Updated Category News Views 169

FRE Nicotine Pouches and PBR: A Thrilling Partnership Ahead In an exciting development for sports enthusiasts, FRE® Nicotine Pouches has joined forces with Professional Bull Riders (PBR) as their official partner for the iconic Unleash The Beast event series. This remarkable multi-year sponsorship marks a significant milestone for FRE, making it their biggest sports...

Continue Reading
ADP Strengthens Workforce Management with WorkForce Software

Updated Category News Views 92

ADP Expands Its Workforce Management Solutions ADP (NASDAQ: ADP), a leading global technology company in human capital management (HCM) solutions, has made a significant move by acquiring WorkForce Software. This strategic acquisition aims to enhance ADP's workforce management offerings and bolster innovation to address the evolving needs of businesses worldwide....

Continue Reading
MiniLuxe Secures Funding through Innovative Private Placement

Updated Category News Views 305

MiniLuxe Announces a Strategic Private Placement MiniLuxe Holding Corp. has recently made headlines by initiating a non-brokered private placement aimed at raising up to $5 million. This move is geared toward furthering the company’s growth trajectory and expanding its footprint in the beauty and self-care industry. Offering Details and Investor Opportunities This...

Continue Reading